Market Overview

Bruker, Erasmus Medical Center Sign Exclusive Licensing Agreement

Bruker (NASDAQ: BRKR) today announces an exclusive licensing agreement with Erasmus
Medical Center, Rotterdam, The Netherlands for rapid testing of
beta-lactamase activity using MALDI-TOF technology. This new method is
fully compatible with the well-established Bruker MALDI Biotyper
system, which is used for MALDI-TOF mass spectrometry-based
identification of microorganisms in over 700 clinical and non-clinical
microbiology laboratories worldwide.

“The Bruker MALDI Biotyper System.” (Photo: Business Wire)

In many laboratories, the MALDI Biotyper has replaced classical
biochemical testing for bacterial identification in the past five years
due to the accuracy, speed, extensive species coverage, ease of use and
cost effectiveness of the system. Classical biochemical techniques
depend upon detecting different metabolic properties of

See full press release

Posted-In: News Guidance Contracts Global

 

Most Popular

Related Articles (BRKR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free